Recombinant Human TRANCE/RANK L/TNFSF11 (E. coli-expressed)
Recombinant Human TRANCE/RANK L/TNFSF11 (E. coli-expressed) Summary
Product Specifications
Arg85-Asp245, with an N-terminal Met
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
6449-TEC
| Formulation | Lyophilized from a 0.2 μm filtered solution in MES and NaCl with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
6449-TEC/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in MES and NaCl. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant Human TRANCE/RANK L/TNFSF11 (Catalog # 6449-TEC) has a molecular weight (MW) of 55.4 kDa as analyzed by SEC-MALS, suggesting that this protein is a homotrimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).
View Larger
Recombinant Human TRANCE/RANK L/TNFSF11 (6449-TEC) induces osteoclast differentiation of the RAW264.7 mouse monocyte/macrophage cell line. The ED50 for this effect is 2-12 ng/mL.
Reconstitution Calculator
Background: TRANCE/TNFSF11/RANK L
RANK L (receptor activator of NF-kappa B ligand), also called TRANCE (TNF-related activation-induced cytokines), OPGL (osteoprotegerin ligand), or ODF (osteoclast differentiation factor), is a 39‑45 kDa type II transmembrane (TM) protein in the tumor necrosis factor family, designated TNFSF11 (1‑5). RANK L, produced by osteoblasts and bone marrow stromal cells, is required for differentiation of osteoclasts and stimulates bone resorption (4, 6). It is also produced by activated T cells and augments dendritic cell stimulation; RANK L-/- mice lack lymph nodes and have impaired thymocyte development (1‑3, 6). The human RANK L cDNA encodes 317 amino acids (aa), including a 47 aa cytoplasmic domain, a 21 aa TM region, and a 249 aa extracellular domain (ECD) with two potential N‑linked glycosylation sites (note: Arg85‑Asp245 of Accession # AAC51762 is identical to Arg157‑Asp317 of SwissProt # O14788. This aa range contains the ECD trimerization and receptor‑binding motifs, but not ECD proteolytic cleavage sites). Within the ECD, human RANK L shares 89%, 89%, 93% and 95% aa identity with mouse, rat, bovine and porcine RANK L, respectively. Mouse RANK L can stimulate human osteoclast differentiation (4). Like most TNF family members, RANK L can form trimers (1). Soluble 31, 25 and 24 kDa forms of RANK L can be created by usage of alternate start sites at aa 74 or 146, or proteolytic cleavage by osteoblast- or stromal cell‑derived ADAM10 (after aa 139) or MMP14 (aa 146), or bone metastatic prostate tumor-derived MT1-MMP (aa 146) (5, 7, 8). Both TM and soluble extracellular RANK L act by engaging RANK receptors and are antagonized by the decoy receptor, OPG (osteoprotegrin) (2, 5). In resting cells, the majority of RANK L is stored in secretory lysosomes (9). In mammary epithelia, RANK L is upregulated by pregnancy hormones and is essential for the formation of a lactating mammary gland (10). In the brain, astrocyte RANK L mediates body temperature regulation (11). Pathologically, RANK L is thought to mediate post-menopausal osteoporosis, vascular calcification, progestin-induced breast cancer, cancer-induced bone disease, and osteopetrosis (in RANK L deficiencies) (12‑16).
- Leibbrandt, A. and J.M. Penninger 2008) Ann. N. Y. Acad. Sci. 1143:123.
- Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190.
- Anderson, D.M. et al. (1997) Nature 390:175.
- Lacey, D.L. et al. (1998) Cell 93:165.
- Hikita, A. et al. (2006) J. Biol. Chem. 281:36846.
- Kong, Y-Y. et al. (1999) Nature 397:315.
- Accession #NP_143026 and EAX08679.
- Sabbota, A.L. et al. (2010) Cancer Res. 70:5558.
- Aoki, S. et al. (2010) J. Bone Miner. Res. 25:1907.
- Fata, J.E. et al. (2000) Cell 103:41.
- Hanada, R. et al. (2009) Nature 426:505.
- Osako, M.K. et al. (2010) Circ. Res. 107:466.
- Schramek, D. et al. (2010) Nature 468:98.
- Gonzalez-Suarez, E. et al. (2010) Nature 468:103.
- Dougall, W.C. and M. Chaisson (2006) Cancer Metastasis Rev. 25:541.
- Sobacchi, C. et al. (2007) Nat. Genet. 39:960.
Citations for Recombinant Human TRANCE/RANK L/TNFSF11 (E. coli-expressed)
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Bacterial infections exacerbate myeloma bone disease
Authors: R Liu, Y Zhong, R Chen, S Chen, Y Huang, H Liu
Journal of Translational Medicine, 2022-01-06;20(1):16.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Plastrum testudinis extract suppresses osteoclast differentiation via the NF-&kappaB signaling pathway and ameliorates senile osteoporosis
Authors: H Chen, G Shen, Q Shang, P Zhang, D Yu, X Yu, Z Zhang, W Zhao, Z Wu, F Tang, Liang, X Jiang, H Ren
Journal of ethnopharmacology, 2021-05-08;276(0):114195.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways
Mol Med Rep, 2016-08-25;14(4):3620-6.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
-
What are the differences between the Recombinant Human TRANCE/RANK L/TNFSF11 Protein (Catalog # 390-TN) and the Recombinant Human TRANCE/RANK L/TNFSF11 (Catalog # 6449-TEC)?
6449-TEC is the truncated version of 390-TN, and it contains a 10-His tag in the N-terminus. The bioactivity of 390-TN and 6449-TEC are measured in the same assay described in the datasheet, "Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells." However, 390-TN utilizes a cross-linking antibody, MAB050, as it requires receptor trimerization which results in higher bioactivity. The ED50 for 390-TN is 1.5-7.5 ng/mL in the presence of MAB050, while the ED50 for 6449-TEC is 2-12 ng/mL.
Reviews for Recombinant Human TRANCE/RANK L/TNFSF11 (E. coli-expressed)
There are currently no reviews for this product. Be the first to review Recombinant Human TRANCE/RANK L/TNFSF11 (E. coli-expressed) and earn rewards!
Have you used Recombinant Human TRANCE/RANK L/TNFSF11 (E. coli-expressed)?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
